This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Indegene Limited has informed the Exchange about Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Smallcap 250 and 2.4 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indegene's Board approved unaudited Q2 and H1 FY26 financial results (ended September 30, 2025) with an unmodified auditor opinion from Deloitte Haskins & Sells. Consolidated revenue grew to ₹8,042 million in Q2 FY26 (up ~17% from ₹6,868 million in Q2 FY25) and ₹15,650 million for H1 FY26 (up ~14.8% from ₹13,633 million). Consolidated profit after tax rose to ₹1,021 million in Q2 (up ~11%) and ₹2,185 million in H1 (up ~22%). The Board also approved allotment of shares under ESOP/RSU/CSOP plans, an investment of up to Euro 8.5 million in wholly owned subsidiary Indegene Ireland Limited for capex, and noted the ongoing BioPharm acquisition (USD 104 million, effective October 1, 2025) and Warn and Co acquisition (GBP 3 million, signed October 16, 2025). A U.S. class action lawsuit (TCPA-related) was allowed to proceed in July 2025; no provision has been made as the financial impact cannot be reliably estimated.
Steady double-digit revenue and profit growth continues, though PAT growth has moderated compared to FY25's pace. Multiple acquisitions (BioPharm, Warn and Co) and subsidiary investments signal aggressive expansion, which could pressure margins in the near term. The U.S. class action lawsuit remains a watch item, but the absence of any provision limits immediate financial impact.
| Q2 FY26 | Q2 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹804.2 Cr | ₹686.8 Cr | +17.1% |
| Operating profit | ₹113.4 Cr | ₹102.7 Cr | +10.4% |
| Profit after tax | ₹102.1 Cr | ₹91.70 Cr | +11.3% |
| EBITDA margin | 17.5% | 18.4% | −0.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.